Clinical trial

Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases

NCT06676917

Study summary

ClinicalTrials.gov

Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Datopotamab deruxtecan Normalized identity: datopotamab deruxtecan View linked drug · Find medicine records · Find other trials using this name

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2025-06-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Datopotamab deruxtecanDRUG · verified · RxNorm: datopotamab deruxtecan

Sponsors & collaborators

MedSIRlead sponsor

Daiichi Sankyocollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06676917 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.